Biotech breakout alert! Which under-$5 stocks could double on FDA news like AQST?

**Biotech stocks with potential for FDA news-driven growth**: 1. **XFOR (X4 Pharmaceuticals)**: With a closing price of $1.82 on July 25, 2025, X4 Pharmaceuticals is positioned for a possible surge if its drug development meets FDA expectations. Biotech Theme; Closing Price < $5; Potential FDA News Catalyst |code|stock code|stock name|Last Price|Last Change|Percentage Change in Price Target|Rating Date|GICS Industry|Closing Price[20250725]|Trading Date|market_code| |---|---|---|---|---|---|---|---|---|---|---| |XFOR|XFOR.O|X4 Pharmaceuticals|1.82|-0.5464479999999999|3.666667|20250502|Biotechnology|1.82|20250725|186| |VOR|VOR.O|Vor Biopharma|2.2|1.382488|3|20250627|Biotechnology|2.2|20250725|185| |MDCX|MDCX.O|Medicus Pharma|2.93|-2.980132|1|20250508|Biotechnology|2.93|20250725|186| |KPTI|KPTI.O|Karyopharm|4.35|-1.805869|1|20250513|Biotechnology|4.35|20250725|185| |PROK|PROK.O|ProKidney|3.29|0.9202449999999999|1|20250715|Biotechnology|3.29|20250725|186| |MDCX|MDCX.O|Medicus Pharma|2.93|-2.980132|0.928571|20250512|Biotechnology|2.93|20250725|186| |LSTA|LSTA.O|Lisata Therapeutics|2.69|1.12782|0.6|20250715|Biotechnology|2.69|20250725|186| |IMDX|IMDX.O|Insight Molecular|2.885|-2.533784|0.6|20250521|Biotechnology|2.885|20250725|186| |REPL|REPL.O|Replimune Group|3.15|1.612903|0.5714290000000001|20250602|Biotechnology|3.15|20250725|185| |RCKT|RCKT.O|Rocket|3.14|-2.180685|0.5|20250516|Biotechnology|3.14|20250725|185| 2. **VOR (Vor Biopharma)**: Trading at $2.2, Vor Biopharma has a slight edge over X4 Pharmaceuticals, but its $3% price target suggests room for growth upon FDA news. 3. **MDCX (Medicus Pharma)**: Currently at $2.93, Medicus Pharma has a mixed outlook with a slight increase in its price target, indicating cautious optimism ahead of potential FDA decisions. 4. **KPTI (Karyopharm)**: With a closing price of $4.35, Karyopharm is closer to the $5 mark but could still benefit from FDA news, especially if its drug pipeline meets regulatory expectations. 5. **PROK (ProKidney)**: ProKidney's $3.29 closing price and recent positive developments make it a contender for a FDA-driven surge, especially with a price target that suggests potential upside. **Conclusion**: These under-$5 biotech stocks have shown varying degrees of potential in response to FDA news catalysts. Investors should conduct thorough due diligence, considering the risks and rewards associated with each stock's FDA news exposure. While there is no guarantee of a doubling event, these stocks offer significant upside potential for those willing to take on the biotech sector's inherent risks.